ETF Analysis: The iShares Dow Jones U.S. ETF (IYY) has an implied analyst target price of $178.58, indicating a potential upside of 9.53% from its current trading price of $163.04.
Notable Holdings: Key underlying holdings with significant upside potential include First Horizon Corp (10.63% upside), Exelixis Inc (10.12% upside), and Evercore Inc (10.06% upside) based on their respective analyst target prices.
Analyst Target Justification: The article raises questions about whether analysts' target prices are justified or overly optimistic, suggesting that high targets may lead to downgrades if they do not align with current market conditions.
Further Research Needed: Investors are encouraged to conduct additional research to assess the validity of the analysts' targets in light of recent developments in the companies and their industries.
Wall Street analysts forecast EXEL stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for EXEL is 44.09 USD with a low forecast of 30.00 USD and a high forecast of 52.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
16 Analyst Rating
Wall Street analysts forecast EXEL stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for EXEL is 44.09 USD with a low forecast of 30.00 USD and a high forecast of 52.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
7 Buy
8 Hold
1 Sell
Moderate Buy
Current: 44.500
Low
30.00
Averages
44.09
High
52.00
Current: 44.500
Low
30.00
Averages
44.09
High
52.00
H.C. Wainwright
Robert Burns
Buy
maintain
$49 -> $52
2026-01-08
Reason
H.C. Wainwright
Robert Burns
Price Target
$49 -> $52
AI Analysis
2026-01-08
maintain
Buy
Reason
H.C. Wainwright analyst Robert Burns raised the firm's price target on Exelixis (EXEL) to $52 from $49 and keeps a Buy rating on the shares after the company announced a strategic collaboration with Natera (NTRA). The firm believes the key value driver for the near- to medium-term will be sentiment on the commercial future of zanzalintinib across various tumor types.
Morgan Stanley
Overweight -> Equal Weight
downgrade
$45 -> $48
2026-01-08
Reason
Morgan Stanley
Price Target
$45 -> $48
2026-01-08
downgrade
Overweight -> Equal Weight
Reason
Morgan Stanley downgraded Exelixis to Equal Weight from Overweight with a price target of $48, up from $45. Following 28% share price appreciation over the past 12 months, shares now trades only about 10% below the firm's new price target, the analyst noted. The firm sees 2026 as the first year towards commercialization of Zanzalitinib across multiple oncology indications and while it also models "Zanza"-associated catalysts events, these are factored already into its price target, the analyst added.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for EXEL
Unlock Now
BofA
Neutral -> Underperform
downgrade
$43 -> $41
2026-01-05
Reason
BofA
Price Target
$43 -> $41
2026-01-05
downgrade
Neutral -> Underperform
Reason
BofA downgraded Exelixis to Underperform from Neutral with a price target of $41, down from $43, citing valuation and limited high-impact catalysts seen in 2026. The company has limited patent life on Cabometyx with loss of exclusivity by 2031 and has yet to de-risk meaningful peak sales for a follow-on asset, the analyst tells investors.
Wolfe Research
Kalpit Patel
Peer Perform
initiated
2025-11-17
Reason
Wolfe Research
Kalpit Patel
Price Target
2025-11-17
initiated
Peer Perform
Reason
Wolfe Research analyst Kalpit Patel initiated coverage of Exelixis with a Peer Perform rating and no price target. Zanzalintinib is unlikely to fully replenish cabozantinib's potential lost revenues, the analyst tells investors.
About EXEL
Exelixis, Inc. is an oncology company. The Company has produced four marketed pharmaceutical products, two of which are formulations of its flagship molecule, cabozantinib. It is also advancing and evolving its product pipeline portfolio, including its lead investigational asset, zanzalintinib. Cabozantinib is an inhibitor of multiple tyrosine kinases, including MET, AXL, VEGF receptors and RET and has been also approved as CABOMETYX tablets for advanced renal cell carcinoma, for previously treated hepatocellular carcinoma and for previously treated, radioactive iodine-refractory differentiated thyroid cancer, and as COMETRIQ capsules for progressive, metastatic medullary thyroid cancer. The Company's other two products are COTELLIC, an inhibitor of MEK approved as part of multiple combination regimens to treat specific forms of advanced melanoma and MINNEBRO an oral, non-steroidal, selective blocker of the mineralocorticoid receptor approved the treatment of hypertension in Japan.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
